...
首页> 外文期刊>Clinical and vaccine immunology: CVI >Detection of anti-leishmania (Leishmania) chagasi immunoglobulin G by flow cytometry for cure assessment following chemotherapeutic treatment of American visceral leishmaniasis.
【24h】

Detection of anti-leishmania (Leishmania) chagasi immunoglobulin G by flow cytometry for cure assessment following chemotherapeutic treatment of American visceral leishmaniasis.

机译:检测anti-leishmania chagasi(利什曼虫)免疫球蛋白G的流式细胞术治疗评估后化疗治疗美国的内脏利什曼病。

获取原文
获取原文并翻译 | 示例
           

摘要

The residual serological reactivity observed in patients cured of visceral leishmaniasis (VL) represents the major factor underlying the low efficiency of most anti-Leishmania serological approaches to assess posttherapeutic cure in VL. Herein, we have described a detuned flow cytometry-based methodology to detect anti-live (FC-ALPA-immunoglobulin G [IgG]) and anti-fixed (FC-AFPA-IgG) L. chagasi promastigote IgG, along the titration curve (1:2,000 to 1:128,000), as a tool to assess late (12 months after treatment [12 mAT]) and early (2 and 6 mAT) posttherapeutic cure of pediatric American visceral leishmaniasis. Reactivities were reported as the percentage of positive fluorescent parasite (PPFP), using a PPFP of 50% as a cutoff to segregate positive and negative results. Our data demonstrated that both FC-ALPA-IgG at 1:4,000 and FC-ALPA-IgG at 1:32,000 are useful for late cure assessment in VL, with 100% specificity and outstanding likelihood ratio indices. Cure assessment at 6 mAT also showed promising performance indices, identifying 81% and 71.4% of the treated patients with negative results. However, new interpretation parameters were necessary to monitor cure at 2 mAT. We then introduced the differential PPFP (DeltaPPFP) of 25% as a new cutoff for early cure assessment at specific serum dilutions to analyze IgG reactivity by FC-ALPA-IgG and FC-AFPA-IgG. Our data demonstrated that at 2 mAT, DeltaPPFP was >25% in 60% and 57.1% of treated patients, whereas at 6 mAT, a DeltaPPFP of >25% was observed in 100% and 95.2% of samples assayed by FC-ALPA-IgG and FC-AFPA-IgG, respectively. Together, our findings showed the potential of both FC-ALPA-IgG and FC-AFPA-IgG regarding their applicability to detect differential serological reactivity and further contribution to posttherapeutic cure assessment in VL.
机译:剩余血清学反应中观察到患者治愈的内脏利什曼病(重要)代表了潜在的低的主要因素大多数anti-Leishmania血清学的效率在重要的方法来评估posttherapeutic治愈。在此,我们描述了失谐流检测anti-live cytometry-based方法论(FC-ALPA-immunoglobulin G(免疫球蛋白))和anti-fixed(FC-AFPA-IgG) l . chagasi promastigote免疫球蛋白,1:128,000滴定曲线(下),作为一个工具来评估末(12个月后治疗[12垫])和早期posttherapeutic(2和6垫)美国儿科治疗内脏利什曼病。比例的积极的荧光寄生虫(PPFP),用50%的PPFP截止隔离积极和消极的结果。证明FC-ALPA-IgG 1:4,000和对于治疗晚期FC-ALPA-IgG 1:32,000是有用的在重要的评估,特异性和100%杰出的似然比指数。评估在6垫还显示有前途性能指标,确定的81%和71.4%患者的治疗结果。然而,新解释参数必要的监控治疗2垫。我们介绍了微分PPFP (DeltaPPFP)25%作为早期治疗评估一个新的截止特定的血清稀释分析免疫球蛋白反应性FC-ALPA-IgG和FC-AFPA-IgG。数据表明,2席,DeltaPPFP> 25%, 60%和57.1%的病人,治疗而在6席,DeltaPPFP > 25%观察到样品化验的100%和95.2%FC-ALPA-IgG FC-AFPA-IgG,分别。在一起,我们的研究结果显示的潜力FC-ALPA-IgG和FC-AFPA-IgG关于他们适用于微分血清学检测反应性,进一步的贡献在六世posttherapeutic治疗评估。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号